In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning October 1, 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial and community plans.
This article has been updated.
In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning October 1, 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial and community (but not Medicare Advantage) plans.
The reference bevacizumab (Avastin) and trastuzumab (Herceptin) will no longer be preferred products.
Additionally, other biosimilars, not yet launched in the United States, will not be preferred oncology products. In documents related to community plans, UnitedHealthcare indicated that Pfizer’s bevacizumab biosimilar (Zirabev), and trastuzumab biosimilars made by Celltrion and Teva (Herzuma), Mylan and Biocon (Ogivri), Samsung Bioepis (Ontruzant), and Pfizer (Trazimera) will be non-preferred products.
Other changes taking place on October 1 include listing biosimilar filgrastim (Zarxio), made by Sandoz, as a preferred product. Use of Zarxio will be required before use of follow-on filgrastim (Granix), brand-name filgrastim (Neupogen), or Pfizer’s biosimilar product (Nivestym).
Earlier this year, UnitedHealthcare announced that, in the case of pegfilgrastim, it would prefer Amgen’s brand-name pegfilgrastim, Neulasta, or Neulasta Onpro, a presentation of the pegfilgrastim product in an on-body injector device. Use of these products have, since July 1, been required before use of Mylan and Biocon’s biosimilar (Fulphila), or Coherus BioSciences’ biosimilar (Udenyca).
UnitedHealthcare also currently prefers other reference products to biosimilars; Brand-name infliximab (Remicade) is preferred over Celltrion and Pfizer’s biosimilar (Inflectra), and Samsung Bioepis and Merck’s biosimilar (Renflexis).
However, a representative from UnitedHealthcare previously told The Center for Biosimilars® in an email that, in October 2019 a change will take effect adding Inflectra to a preferred position along with Remicade. As such, beginning October 1, both Remicade and Inflectra will be preferred options for UnitedHealthcare commercial members.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.